Frontlight ResearchEarly access
Not yet taking people in LatviaPhase 1
Tests TQS-168 safety in people with amyotrophic lateral sclerosis
Tests the drug TQS-168 in adults with amyotrophic lateral sclerosis, a nerve disease.
Key facts
- Who runs it
- Tranquis Therapeutics Inc.
- Where
- Riga, LatviaSee the site
- Trial code
- EU 2023-504746-54-00
- U1111-1290-3098
- Registry title
- A PHASE 1B, MULTICENTER, RANDOMIZED, PLACEBO- CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND BIOLOGICAL ACTIVITY OF TQS-168 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 16 people, planned
- Started
- 1 Sept 2023
- Planned end
- 31 Jul 2024
- Type of study
- Interventional
- Record updated
- 11 October 2023
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with amyotrophic lateral sclerosis (ALS). It tests the safety and biological activity of TQS-168 compared with a placebo.
- Age
- 18 years or older
- Sex
- Men and women can join
Where in Latvia
- Pauls Stradins Clinical University HospitalRiga, LatviaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Tests TQS-168 safety in people with amyotrophic lateral sclerosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 11 October 2023